Michael E Bristow

US Patent:

7678824, Mar 16, 2010

Filed:

Sep 14, 2005

Appl. No.:

11/226908

Inventors:

Stephen B. Liggett - Clarksville MD, US
Michael Bristow - Englewood CO, US

Assignee:

The Regents of the University of Colorado, A Body Corporate - Boluder CO

International Classification:

A61K 31/405
A61P 43/00
C12Q 1/68
C07H 21/02
C07H 21/04
G01N 33/53
A61K 47/00

US Classification:

514415, 514789, 435 6, 435 71, 536 235, 536 2431

Abstract:

The present invention concerns the use of methods for evaluating bucindolol treatment for a patient, particularly one with heart failure. It concerns methods for determining whether to administer or prescribe bucindolol to a patient based on whether the patient is homozygous for the Arg 389 polymorphism in the β1-adrenergic receptor (AR).

US Patent:

8080578, Dec 20, 2011

Filed:

Aug 13, 2007

Appl. No.:

11/838131

Inventors:

Stephen B. Liggett - Clarksville MD, US
Michael Bristow - Englewood CO, US

Assignee:

The Regents of the University of Colorado, a body corporate - Denver CO

International Classification:

A61K 31/405
A61K 47/00
A61P 43/00
C12Q 1/68
C07H 21/02
C07H 21/04
G01N 33/53

US Classification:

514415, 514789, 435 61, 435 611, 435 617, 435 71, 536 235, 536 2431, 530350

Abstract:

The present invention concerns the use of methods for evaluating bucindolol treatment for a patient, particularly one with heart failure. It concerns methods for determining whether to administer or prescribe bucindolol to a patient based on whether the patient is homozygous for the Arg 389 polymorphism in the β1-adrenergic receptor (AR).

US Patent:

8093286, Jan 10, 2012

Filed:

Aug 13, 2007

Appl. No.:

11/838142

Inventors:

Stephen B. Liggett - Clarksville MD, US
Michael Bristow - Englewood CO, US

Assignee:

The Regents of the University of Colorado, a body corporate - Denver CO

International Classification:

A61K 31/405
A61K 47/00
A61P 43/00
C12Q 1/68
C07H 21/02
C07H 21/04
G01N 33/53

US Classification:

514415, 514789, 435 61, 435 611, 435 617, 435 71, 536 235, 536 2431, 530350

Abstract:

The present invention concerns the use of methods for evaluating bucindolol treatment for a patient, particularly one with heart failure. It concerns methods for determining whether to administer or prescribe bucindolol to a patient based on whether the patient is homozygous for the Arg 389 polymorphism in the β1-adrenergic receptor (AR).

US Patent:

20120289573, Nov 15, 2012

Filed:

Dec 1, 2011

Appl. No.:

13/309114

Inventors:

Stephen B. Liggett - Clarksville MD, US
Michael Bristow - Englewood CO, US

International Classification:

A61K 31/4045
C12Q 1/68
A61P 9/00

US Classification:

514415, 435 612

Abstract:

The present invention concerns the use of methods for evaluating bucindolol treatment for a patient, particularly one with heart failure. It concerns methods for determining whether to administer or prescribe bucindolol to a patient based on whether the patient is homozygous for the Arg 389 polymorphism in the β1-adrenergic receptor (AR).

US Patent:

20220338646, Oct 27, 2022

Filed:

Apr 27, 2022

Appl. No.:

17/731064

Inventors:

- McKinney TX, US
Michael Woodford Freitas - Plano TX, US
Michael Kerry Bristow - Shawnee KS, US

Assignee:

McMullen Display Ventures LLC - McKinney TX

International Classification:

A47F 7/00

Abstract:

A display system has a wall having a profile representative of but larger than a profile of a collectible item, the wall has an exterior surface and at least one of an aperture and a concavity, wherein the at least one aperture and concavity has a shape configured to receive the collectible item therethrough or therein, respectively. A method of display includes providing a wall having a profile representative of but larger than a profile of a collectible item, the wall having an exterior surface and providing an aperture or concavity in the wall wherein the aperture or concavity is shaped to at least partially receive the collectible item therethrough or therein, respectively.